{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:22:17Z","timestamp":1788535337055,"version":"build-2803163510"},"reference-count":109,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for control of type 2 diabetes and cardiovascular disease (CVD) risk reduction is increasing. Given the established link between obesity and multiple cancers, there is growing interest in the potential effects of GLP-1RAs on cancer risk reduction. This systematic literature review and meta-analysis evaluated the association between GLP-1RA use and cancer incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted literature searches in MEDLINE and EMBASE databases, covering publications up to September 17th, 2025. Our review included studies among adults receiving GLP-1RAs for any indication that reported effects on cancer incidence of any type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,644 unique citations identified, 139 studies met the inclusion criteria for full-text review. After study exclusion, a total of 78 observational studies were included in the review and meta-analysis. GLP-1RA use was associated with statistically significant reductions in cancer risk for 10 of 13 obesity-associated cancers, specifically colorectal, endometrial, esophageal, gallbladder, liver, ovarian, pancreatic and stomach cancers along with meningioma and multiple myeloma. Compared to insulin specifically, GLP-1RAs provided protective effects against cancer of the colorectum (RR: 0.54, 95% CI: 0.44, 0.66), liver (RR: 0.35, 95% CI: 0.20, 0.62), and pancreas (RR: 0.41, 95% CI: 0.36, 0.48). The risk of developing thyroid cancer was slightly elevated, but not statistically significant, among GLP-1RA users (RR: 1.09, 95% CI: 0.98, 1.21).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pooled estimates of observational studies suggest notable reductions in cancer incidence for several obesity-associated cancers. As GLP-1RA use increases, ongoing safety monitoring and long-term real-world data are essential. The potential role of GLP-1RAs in cancer risk reduction warrants further investigation through large-scale RCTs, alongside balanced risk-benefit discussions with patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748261483767","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:12:45Z","timestamp":1788257565000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"33","author":[{"given":"Isha","family":"Lalani","sequence":"first","affiliation":[{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynaldo","family":"Nambayan","sequence":"additional","affiliation":[{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantelle","family":"Carbonell","sequence":"additional","affiliation":[{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Ruan","sequence":"additional","affiliation":[{"name":"Alberta Health Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan E.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"University of Calgary"},{"name":"Alberta Health Services"},{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Stukalin","sequence":"additional","affiliation":[{"name":"University of Calgary"},{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hilsden","sequence":"additional","affiliation":[{"name":"University of Calgary"},{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-290X","authenticated-orcid":false,"given":"Darren R.","family":"Brenner","sequence":"additional","affiliation":[{"name":"University of Calgary"},{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0016-2"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78371"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1645"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/M24-0019"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.09.005"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00933-4"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.03.014"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21499"},{"issue":"2","key":"e_1_3_6_10_2","first-page":"S94","article-title":"Weight control and physical activity in cancer prevention: international evaluation of the evidence","volume":"11","author":"Vainio H","year":"2002","unstructured":"Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev. 2002;11(Suppl 2):S94-S100.","journal-title":"Eur J Cancer Prev"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020485"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15382"},{"key":"e_1_3_6_19_2","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj-British Medical Journal. 2021;372."},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"S1364","DOI":"10.14309\/01.ajg.0001036968.88400.f3","article-title":"S1900 GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes","volume":"119","author":"Alsakarneh S","year":"2024","unstructured":"Alsakarneh S, Madi M, Abuassi M, et al. S1900 GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes. Official journal of the American College of Gastroenterology | ACG. 2024;119:S1364.","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17925"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000712"},{"key":"e_1_3_6_23_2","first-page":"S1","article-title":"SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND REDUCED RISK OF LIVER CANCER IN PEOPLE WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY","volume":"78","author":"Huang P-C","year":"2023","unstructured":"Huang P-C, Sheng-Kai Ma K. SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND REDUCED RISK OF LIVER CANCER IN PEOPLE WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY. Hepatology. 2023;78:S1-S2154.","journal-title":"Hepatology"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001037700.41113.c9"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4661"},{"key":"e_1_3_6_26_2","first-page":"S1","article-title":"LONG-TERM HEPATOPROTECTIVE EFFECTS OF GLP-1RA IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY","volume":"80","author":"Khataniar H","year":"2024","unstructured":"Khataniar H, Dharia A, Desai A, et al. LONG-TERM HEPATOPROTECTIVE EFFECTS OF GLP-1RA IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY. Hepatology. 2024;80:S1-S2011.","journal-title":"Hepatology"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70069"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10752-9"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18502"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.130"},{"key":"e_1_3_6_31_2","first-page":"S1","article-title":"GLP-1'S ROLE IN LOWERING HCC RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS AND TYPE 2 DIABETES \u2013 A MULTICENTER PROPENSITY-MATCHED STUDY","volume":"80","author":"Sohail A","year":"2024","unstructured":"Sohail A, Aslam A, Brown K. GLP-1'S ROLE IN LOWERING HCC RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS AND TYPE 2 DIABETES \u2013 A MULTICENTER PROPENSITY-MATCHED STUDY. Hepatology. 2024;80:S1-S2011.","journal-title":"Hepatology"},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.14309\/01.ajg.0000778232.15515.30","article-title":"S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC?","volume":"116","author":"Trujillo S","year":"2021","unstructured":"Trujillo S, Kamionkowski S, Walsh E, Davila J, Asaad I. S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC? Official journal of the American College of Gastroenterology | ACG. 2021;116:S547-S548.","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.04.029"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13751"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)01673-3"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112407"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2681"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70090"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.1096"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16445"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)00831-6"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003760"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01558-1"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0105"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02466-4"},{"key":"e_1_3_6_46_2","article-title":"Tu1944 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH LOWER INCIDENCE OF HEPATOBILIARY OR PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A MULTI-CENTER COHORT STUDY ACROSS THE UNITED STATES","volume":"166","author":"Nieto LM","year":"2024","unstructured":"Nieto LM, Narvaez S, Argueta PP, Martinez J, Vega KJ, Davisson L. Tu1944 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH LOWER INCIDENCE OF HEPATOBILIARY OR PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A MULTI-CENTER COHORT STUDY ACROSS THE UNITED STATES. Gastroenterology. 2024;166:S-1472-S-1473.","journal-title":"Gastroenterology"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001028388.64456.1e"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091625"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i581"},{"key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.14309\/01.ajg.0000950004.68230.50","article-title":"S91 Risk of Pancreatic Adenocarcinoma in Patients on Oral Hypoglycemic Agents for Type 2 Diabetes Mellitus","volume":"118","author":"Babajide O","year":"2023","unstructured":"Babajide O, Desai A, Adekunle A, et al. S91 Risk of Pancreatic Adenocarcinoma in Patients on Oral Hypoglycemic Agents for Type 2 Diabetes Mellitus. Official journal of the American College of Gastroenterology | ACG. 2023;118:S73-S74.","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12230"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13739"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002197"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0075"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae260"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010078"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13597"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2021.1955255"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.402"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajmo.2025.100114"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101346"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.09.004"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06453-z"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(24)01662-7"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2068-3"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001033652.14646.a5"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5573"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101624"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101695"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4880"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01444-0"},{"key":"e_1_3_6_74_2","first-page":"100370","article-title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study","volume":"38","author":"Krishnan A","year":"2024","unstructured":"Krishnan A, Schneider CV, Arkenau HT, et al. Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study. J Clin Transl Endocrinol. 2024;38:100370.","journal-title":"J Clin Transl Endocrinol"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05508-1"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183224"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001032164.05931.aa"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.10557"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01551-8"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0802"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S171503"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1174"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14287"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09076-z"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132377"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001486"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05972-x"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.228"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15248"},{"key":"e_1_3_6_90_2","first-page":"25331594","article-title":"Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus","author":"Hong G","year":"2025","unstructured":"Hong G, Patel D, Elangovan A, et al. Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus. medRxiv. 2025:25331594. 2025.07.18.","journal-title":"medRxiv"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9712"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0277"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1678"},{"key":"e_1_3_6_96_2","first-page":"5","article-title":"Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders","volume":"85","author":"Bremmer MP","year":"2024","unstructured":"Bremmer MP, Hendershot CS. Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders. Journal of Studies on Alcohol and Drugs. 2024;85:5-10.","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13211"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17190-3"},{"key":"e_1_3_6_99_2","first-page":"A235","article-title":"Change in alcohol consumption following liraglutide initiation: a real life experience","volume":"60","author":"Kalra S","year":"2011","unstructured":"Kalra S, Kalra B, Sharma A. Change in alcohol consumption following liraglutide initiation: a real life experience. Diabetes. 2011;60:A235-A352.","journal-title":"Diabetes"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863"},{"key":"e_1_3_6_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2"},{"key":"e_1_3_6_102_2","doi-asserted-by":"crossref","unstructured":"Richards JR Dorand MF Royal K Mnajjed L Paszkowiak M Simmons WK. Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. J Clin Psychiatry. 2023;85.","DOI":"10.4088\/JCP.23m15068"},{"key":"e_1_3_6_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47644"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114565"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2418398"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntab066"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.30904"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01871"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261483767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748261483767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261483767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:49:56Z","timestamp":1788533396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748261483767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":109,"alternative-id":["10.1177\/10732748261483767"],"URL":"https:\/\/doi.org\/10.1177\/10732748261483767","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748261483767\/v4\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v4\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261483767\/v3\/decision1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"10732748261483767"}}